DSM determined to make acquisitions.

DSM, the Dutch based chemicals company, said the long-considered purchase of a stake in the chemicals specialist Rhodia of the Aventis pharmaceuticals group is no longer an option. DSM has lately been associated with many possible purchasing opportunities in specialty chemicals and there is ongoing speculation about the acquisition of the Swiss Lonza Group. DSM holds a fund of € 6.000 million and will use it to purchase a company, via which the Dutch company would increase its turnover growth from the present € 5.700 million annually to € 10.000 million in 2005.
Share
STIJGERS & DALERS BEL20